Edition:
India

Allergan Reports Third Quarter 2019 Financial Results


Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Allergan Plc ::ALLERGAN REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 GAAP LOSS PER SHARE $2.40.Q3 EARNINGS PER SHARE ESTIMATE $4.22 -- REFINITIV IBES DATA.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.25.Q3 2019 GAAP NET REVENUES OF $4.05 BILLION.Q3 REVENUE VIEW $3.88 BILLION -- REFINITIV IBES DATA.REAFFIRMS GUIDANCE FOR FULL-YEAR 2019 NON-GAAP PERFORMANCE NET INCOME PER SHARE.RAISES GUIDANCE FOR FULL-YEAR 2019 NET REVENUE.QTRLY RESTASIS NET REVENUES WERE $286.8 MILLION, A DECREASE OF 3.8 PERCENT VERSUS THE PRIOR YEAR QUARTER.RECORDED A PRE-TAX CHARGE OF $750 MILLION IN THREE MONTHS ENDED SEPTEMBER 30, 2019.SEES FY GAAP REVENUE $15.625 BILLION - $15.825 BILLION.ALLERGAN - PRE-TAX CHARGE OF $750 MILLION RELATED TO SETTLEMENT REACHED IN PRINCIPLE BY UNITS WITH DIRECT PURCHASERS OF NAMENDA.SEES FY NON-GAAP REVENUE ABOUT $15.600 BILLION - $15.800 BILLION.IN U.S. SPECIALIZED THERAPEUTICS, QTRLY BOTOX COSMETIC NET REVENUE $237.6 MILLION, UP 10%.ALLERGAN AND ABBVIE CONTINUE TO EXPECT TO CLOSE THE TRANSACTION IN EARLY 2020.ALLERGAN - PRE-TAX CHARGE RESOLVING CLASS ACTION LITIGATION FILED BY CLASS OF PURCHASERS IN U.S. DISTRICT COURT FOR SOUTHERN DISTRICT OF NEW YORK.FY2019 EARNINGS PER SHARE VIEW $16.73, REVENUE VIEW $15.56 BILLION -- REFINITIV IBES DATA.SEES FY GAAP EARNINGS PER SHARE OVER $14.98.